

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司\*

*(Incorporated in Bermuda with limited liability)*

(Stock Code: 00858)

### APPOINTMENT OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Wong Sau Kuen (“**Ms. Wong**”), an executive Director of the Company, has been appointed as a joint company secretary of the Company (the “**Joint Company Secretary**”) with effect from 8 January 2014. Mr. Liu Kwok Wah (“**Mr. Liu**”), an executive Director of the Company, will continue to act as the other Joint Company Secretary.

Ms. Wong, aged 50, joined the Group in May 2008 as an assistant to the Board and was appointed as an executive Director and an authorised representative of the Company with effect from 6 October 2008. She has also become directors of certain members of the Group since then. Since she joined the Group, she has been providing full company secretarial and corporate compliance support to the Board and the Group, and has acted as company secretary of various subsidiaries of the Company since 2009. Ms. Wong has more than 20 years of experience in both the commercial and industrial sectors including the PRC pharmaceutical market. She has extensive experience in areas of business administration and internal control.

Ms. Wong does not possess the academic or professional qualifications as stipulated under Note 1 to Rule 3.28 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board has applied to the Stock Exchange, and has been granted, a waiver from strict compliance with the requirements under Rule 3.28 and Rule 8.17 of the Listing Rules for a period of three years from the date of appointment of Ms. Wong as the Joint Company Secretary on the conditions that (i) Ms. Wong would be assisted by Mr. Liu during the waiver period to acquire the “relevant experience” under Note 2 to Rule 3.28 of the Listing Rules and to discharge her duties as a company secretary of the Company, and this waiver would be revoked immediately if Mr. Liu ceases to provide assistance to Ms. Wong; and (ii) the Company should notify the Stock Exchange at the end of the waiver period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that, at the end of the waiver period, the Company

would be able to demonstrate that Ms. Wong could satisfy the requirements under Rule 3.28 of the Listing Rules after having the benefit of Mr. Liu's assistance such that a further waiver would not be necessary.

The Board would like to take this opportunity to welcome Ms. Wong on her new appointment.

By Order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 9 January 2014

*As at the date of this announcement, the executive Directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and the independent non-executive Directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

*\* For identification purpose only*